A61K 31/7115
Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine
Official title: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K31/7115 (Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine) appears on 449 US grants and 939 published applications in this corpus.
Search patents in A61K- Granted patents
- 449
- Published applications
- 939
- Assignees
- 343
- Inventors
- 1,432
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 1 |
| 2002 | 4 | 4 |
| 2003 | 2 | 4 |
| 2004 | 1 | 7 |
| 2005 | 0 | 5 |
| 2006 | 0 | 5 |
| 2007 | 1 | 5 |
| 2008 | 1 | 5 |
| 2009 | 3 | 20 |
| 2010 | 9 | 13 |
| 2011 | 16 | 14 |
| 2012 | 9 | 13 |
| 2013 | 6 | 32 |
| 2014 | 18 | 52 |
| 2015 | 25 | 33 |
| 2016 | 24 | 40 |
| 2017 | 29 | 36 |
| 2018 | 23 | 53 |
| 2019 | 41 | 73 |
| 2020 | 33 | 77 |
| 2021 | 33 | 67 |
| 2022 | 47 | 82 |
| 2023 | 30 | 77 |
| 2024 | 39 | 76 |
| 2025 | 32 | 72 |
| 2026 | 12 | 73 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compound, method and pharmaceutical composition for regulating expression of ataxin 315 Sep 2026US 12,735,705 B2Tanabe Pharma Corporation
- RNA molecules, methods of producing circular RNA, and treatment methods15 Sep 2026US 12,737,877 B2Cornell University
- Antagonism as a therapy for TDP-43 proteinopathies25 Aug 2026US 12,716,065 B2University of Southern California
- Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof11 Aug 2026US 12,702,707 B2The Trustees of the University of Pennsylvania
- Therapeutics for glycogen storage disease type iii11 Aug 2026US 12,703,858 B2Ultragenyx Pharmaceutical Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Trems for use in correction of missense mutations1 Oct 2026US 2026/0294955 A1Flagship Pioneering Innovations VI, LLC
- Hiv vaccine24 Sep 2026US 2026/0284176 A1
- Decoy rna oligonucleotides for inhibiting ythdf224 Sep 2026US 2026/0286355 A1Catchme Rna Therapeutics Ltd.
- Oligonucleotides targeting gal3st124 Sep 2026US 2026/0286364 A1
Most cited
By later US patents
- Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof518US 5,550,111 ATemple University of the Commonwealth System of Higher Education · 1996
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015